Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 7
2005 22
2006 16
2007 21
2008 18
2009 30
2010 27
2011 24
2012 15
2013 14
2014 18
2015 14
2016 15
2017 20
2018 15
2019 13
2020 13
2021 19
2022 19
2023 24
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0.63 [95% CI 0.36-0.90; very low]; lemborexant: 0.41 [0.04-0.78; very low]) and eszopiclone was more effective than ramelteon (0.63 [0.16-1.10; very low]) …
For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0.63 [95% CI 0.36-0.90 …
Insomnia Management: A Review and Update.
Shaha DP. Shaha DP. J Fam Pract. 2023 Jul;72(6 Suppl):S31-S36. doi: 10.12788/jfp.0620. J Fam Pract. 2023. PMID: 37549414 Review.
Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpidem, eszopiclone, and zaleplon), low-dose doxepin (tricyclic antidepressant), ramelteon (melatonin receptor agonist), and dual orexin r …
Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpide …
Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
Abad VC, Guilleminault C. Abad VC, et al. Drugs Aging. 2018 Sep;35(9):791-817. doi: 10.1007/s40266-018-0569-8. Drugs Aging. 2018. PMID: 30058034 Review.
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon. ...Suvorexant or low-dose doxepin can improve sl …
This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (e …
Menopause and Sleep Disorders.
Tandon VR, Sharma S, Mahajan A, Mahajan A, Tandon A. Tandon VR, et al. J Midlife Health. 2022 Jan-Mar;13(1):26-33. doi: 10.4103/jmh.jmh_18_22. Epub 2022 May 2. J Midlife Health. 2022. PMID: 35707298 Free PMC article. Review.
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Amitriptyline and other drugs such as Eszopiclone, Escitalopram, Gabapentin, Quiteiapine, Citalopram, Mirtazapine followed by long-acti …
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Am …
Insomnia: Pharmacologic Therapy.
Matheson E, Hainer BL. Matheson E, et al. Am Fam Physician. 2017 Jul 1;96(1):29-35. Am Fam Physician. 2017. PMID: 28671376 Free article. Review.
Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclone, and zaleplon) should be reserved for use if the first-line agents are ineffective. ...
Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclo …
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6. doi: 10.58347/tml.2023.1667a. Med Lett Drugs Ther. 2023. PMID: 36630579 No abstract available.
Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, Shi L, Xiang YJ, Que JY, Yuan K, Deng JH, Teng T, Li YY, Sun W, Sun HQ, Vitiello MV, Tang XD, Zhou XY, Bao YP, Shi J, Lu L. Yue JL, et al. Sleep Med Rev. 2023 Apr;68:101746. doi: 10.1016/j.smrv.2023.101746. Epub 2023 Jan 14. Sleep Med Rev. 2023. PMID: 36701954 Review.
Z-drugs were more efficacious than placebo for SL, WASO, TST and SE, but with higher risk to safety. Zaleplon and eszopiclone had better efficacy than placebo for TST and SQ respectively. MRAs may also be efficacious for sleep-onset insomnia with good safety. ...
Z-drugs were more efficacious than placebo for SL, WASO, TST and SE, but with higher risk to safety. Zaleplon and eszopiclone had bet …
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Sateia MJ, et al. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470. J Clin Sleep Med. 2017. PMID: 27998379 Free PMC article.
(WEAK). We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. ...
(WEAK). We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment …
Sleep interventions for children with attention deficit hyperactivity disorder (ADHD): A systematic literature review.
Larsson I, Aili K, Lönn M, Svedberg P, Nygren JM, Ivarsson A, Johansson P. Larsson I, et al. Sleep Med. 2023 Feb;102:64-75. doi: 10.1016/j.sleep.2022.12.021. Epub 2022 Dec 26. Sleep Med. 2023. PMID: 36603513 Free article. Review.
The studies included behavioral sleep interventions and pharmacological interventions using melatonin and eszopiclone. For six of the seven outcomes, the effect sizes were small to moderate and the certainty of the evidence was low. ...
The studies included behavioral sleep interventions and pharmacological interventions using melatonin and eszopiclone. For six of the …
Pharmacology for sleep disturbance in PTSD.
Lipinska G, Baldwin DS, Thomas KG. Lipinska G, et al. Hum Psychopharmacol. 2016 Mar;31(2):156-63. doi: 10.1002/hup.2522. Epub 2016 Feb 8. Hum Psychopharmacol. 2016. PMID: 26856810 Free article.
There is also high-level evidence supporting use of eszopiclone, as well as risperidone and olanzapine as adjunct therapy. Antidepressants such as sertraline, venlafaxine and mirtazapine, benzodiazepines such as alprazolam and clonazepam and non-benzodiazepine hypnotics su …
There is also high-level evidence supporting use of eszopiclone, as well as risperidone and olanzapine as adjunct therapy. Antidepres …
348 results